In a large study in which vemurafenib was administered to pretreated nonmelanoma BRAF exon 15 p.V600E-mutated patients, an objective response was observed in 42% of NSCLC patients, with a median PFS of 7.3 months and a 12-month PFS rate of 23% [123]. Here, BRAF is linked to non-small cell lung carcinoma.